Overview: NAFLD-Non Alcoholic Fatty Liver Disease Fibrosis Score Panel
Introduction: The Non-Alcoholic Fatty Liver Disease Fibrosis Score Panel is a diagnostic tool designed to assess NAFLD fibrosis risk using serum samples. In India, NAFLD fibrosis/cirrhosis affects ~5-10 percent of NAFLD patients (higher in diabetics/obese), progressing silently to end-stage liver disease or HCC. High morbidity from under-testing in rural/low-SES patients with metabolic risk or elevated ALT, limited non-invasive labs, delayed fibrosis staging leading to missed early intervention or transplant. Per hepatology practices aligned with ICMR and INASL guidelines, the test employs spectrophotometry for ALT, AST, platelet count, albumin, and NAFLD fibrosis score (NFS) calculation over 1-2 days with high accuracy, valuable as non-invasive tool to stratify low/high fibrosis risk. This diagnostic falls under liver function screening and targets NAFLD patients (especially diabetics or obese), addressing accurate detection to guide lifestyle modification, pioglitazone, or specialist referral. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise fibrosis risk assessment and reducing cirrhosis/HCC burden. Its serum-based approach ensures reliable score calculation.
Other Names: NAFLD Fibrosis Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: NFS score standard since 2007; in India, expanding in NAFLD clinics.
Purpose: The test assesses 5 parameters including ALT to guide NAFLD fibrosis risk assessment, stratify severity, inform management.
Test Parameters: 1. ALT, 2. AST, 3. Platelet Count, 4. Albumin, 5. Fibrosis Score.
Pretest Condition: Fasting 10-12 hours recommended; patients should have NAFLD diagnosis.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on diabetes, BMI, ALT history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected fibrosis including cirrhosis, benefits of non-invasive screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and calculate NFS within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or thrombocytopenia can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: NFS >0.676 indicates high fibrosis risk, necessitating specialist input.
Specialist Consultation: Hepatologists should be consulted for management.
Additional Supporting Tests: FibroScan, ELF score for confirmation.
Test Limitations: Indirect score; comprehensive approach required.
References: Indian Journal of Gastroenterology 2024, NAFLD Studies India 2023.
